Atherosclerosis Therapeutics Market 2024-2028: Size and Side-effects associated with atherosclerosis therapeutics; growth driven by the Product, Some of key Companies Positioned Strategically

The atherosclerosis therapeutics market size by Product (Small molecules and Biologics) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 2660.1 million. The market is expected to grow at a CAGR of   4.5% between 2024 and 2028.

• The global atherosclerosis therapeutics market caters to a range of small molecule treatments, including statins, ACE inhibitors, beta-blockers, antiplatelet agents, calcium channel blockers, and nitrates. Statins, specifically, are primary medications for atherosclerosis treatment. While these drugs effectively reduce the risk of atherosclerosis, they may cause side effects. For instance, ZOCOR (simvastatin) is a cholesterol-lowering statin used in conjunction with diet and exercise. It decreases LDL cholesterol levels in the blood, mitigating the primary risk factor for atherosclerosis. Thus, ZOCOR is a crucial medication for preventing plaque formation.
• The Atherosclerosis Therapeutics Market represents a significant business opportunity due to the rising prevalence of cardiovascular diseases and the increasing demand for effective treatments. Key players in this market are developing innovative therapies to address the root causes of atherosclerosis, such as inflammation and plaque formation. These advancements are expected to drive market growth and provide substantial returns for investors. Strategic collaborations and partnerships are also crucial for companies to stay competitive in this dynamic industry.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Amgen Inc.
• AstraZeneca Plc
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Ionis Pharmaceuticals Inc.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/